<DOC>
	<DOCNO>NCT00671073</DOCNO>
	<brief_summary>This study ass safety efficacy range oglemilast dos . The study 14 week duration . All patient meet eligibility criterion randomize one three dos oglemilast placebo .</brief_summary>
	<brief_title>Study To Assess Efficacy Safety Oglemilast Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Presence COPD define GOLD criterion ( 2006 ) ; postbronchodilator FEV1/FVC &lt; 70 % , postbronchodilator FEV1 &gt; 30 % &lt; 80 % predict Current former cigarette smoker Longterm oxygen use &gt; 15 hour day Symptoms consistent significant asthmatic component ( e.g . atopic disease , allergic symptom ) Any COPD exacerbation within 30 day prior study entry runin History chronic recurrent gastrointestinal disorder associate bleed previous 12 month Presence clinical significant pulmonary disease COPD</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Airflow Obstruction , Chronic</keyword>
	<keyword>Chronic Airflow Obstruction</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Chronic Obstructive Airway Disease</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>COAD</keyword>
</DOC>